Brokers Issue Forecasts for PSTV FY2030 Earnings

Plus Therapeutics, Inc. (NASDAQ:PSTV) – HC Wainwright issued their FY2030 EPS estimates for Plus Therapeutics in a note issued to investors on Monday, March 16th. HC Wainwright analyst S. Lee anticipates that the company will post earnings per share of $0.22 for the year. HC Wainwright currently has a “Buy” rating and a $1.00 target price on the stock. The consensus estimate for Plus Therapeutics’ current full-year earnings is ($2.30) per share.

A number of other equities analysts have also commented on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Plus Therapeutics in a report on Thursday, January 22nd. D. Boral Capital dropped their target price on Plus Therapeutics from $5.00 to $4.00 and set a “buy” rating on the stock in a research report on Thursday, January 22nd. Lake Street Capital started coverage on Plus Therapeutics in a research note on Tuesday, February 3rd. They issued a “buy” rating and a $2.00 price target on the stock. Finally, Ascendiant Capital Markets reduced their price target on Plus Therapeutics from $21.00 to $19.00 and set a “buy” rating for the company in a report on Friday, November 21st. Five analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $5.80.

Plus Therapeutics Trading Down 5.6%

PSTV opened at $0.24 on Tuesday. The company has a fifty day simple moving average of $0.29 and a 200 day simple moving average of $0.48. The firm has a market cap of $40.49 million, a price-to-earnings ratio of -0.19 and a beta of 0.79. Plus Therapeutics has a twelve month low of $0.16 and a twelve month high of $2.08.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in PSTV. Susquehanna International Group LLP acquired a new position in Plus Therapeutics during the 3rd quarter worth $46,000. Jane Street Group LLC acquired a new stake in shares of Plus Therapeutics in the 2nd quarter valued at about $41,000. State Street Corp raised its stake in shares of Plus Therapeutics by 37.1% in the 4th quarter. State Street Corp now owns 468,893 shares of the company’s stock valued at $240,000 after purchasing an additional 127,000 shares in the last quarter. Scientech Research LLC bought a new position in shares of Plus Therapeutics during the third quarter worth about $100,000. Finally, XTX Topco Ltd bought a new position in shares of Plus Therapeutics during the fourth quarter worth about $127,000. 3.28% of the stock is currently owned by institutional investors.

Plus Therapeutics Company Profile

Plus Therapeutics is a clinical‐stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company’s lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases.

The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors.